Disease Progression: Various factors that influence HCV disease progression including steatosis, obesity, insulin resistance, diabetes, race/ethnicity, and general studies on disease progression.


        205. 5-Year Follow-Up of Clinical and Histological Changes in Patients With HCV Infection and Initially Mild Liver Disease.

        211. Influence of Cannabis Use on Severity of Hepatitis C Disease (updated November 1, 2006)

        216. Impact of caffeine consumption on histological activity in patients with Chronic Active Hepatitis C (updated November 2, 2006)

        227. The natural history of patients who spontaneously clear HCV (updated October 28, 2006)

        245. Hepatitis C Anti D: Progression with age? (updated October 28, 2006)

        262. Narcotic Analgesics and Progression of Fibrosis in Patients With Chronic Hepatitis C (updated October 31, 2006)

        266. Chronic hepatitis C and outcome of renal transplantation

        277. Mouse Model for HCV Pathogenesis

        318. Hepatitis C virus is present in CD4+ T cells of chronically infected patients impairing their IFN-g production

        347. Fatigue in Patients with Hepatitis C and Non-Viral Chronic Liver Disease. (updated October 28, 2006)

        505. An excess of corrupted humours: healing the liver in 16th -century Europe

        840. Does coffee drinking protect cirrhotic patients against hepatocellular carcinoma? (updated November 2, 2006)

        1296. Quality of care in Chronic Hepatitis C Virus (HCV) Infection

        1147. An Open Label, Comparative, Multicenter Study of Peginterferon Alfa-2a plus Ribavirin in the Treatment of Patients with Chronic Hepatitis C/Hepatitis B Co-Infection versus those with Monoinfected Chronic Hepatitis C: An Interim Report (updated November 2, 2006)


        Metabolic disorders

o       222. Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus (updated October 28, 2006)

o       228. Association between liver fibrosis and insulin sensitivity in chronic hepatitis C patients (updated October 28, 2006)

o       292. Altered Hepatic Metabolic Function in Patients with Chronic Hepatitis C is Associated with Obesity, Insulin Resistance, or Hepatic Steatosis, Independent of Cirrhosis: Results from the HALT-C Trial

o       295. The Role of Hepatitis C Genotype 3 Core Protein Domain 3 in Intrahepatic Steatosis (updated October 28, 2006)

o       308. The Hepatitis C Virus Core Protein of Genotypes 1B and 3A Down-Regulate Insulin Receptor Substrate 1 via Genotype-Specific Mechanisms

o       313. Insulin Resistance and Liver Fibrosis in Virus C Chronic Hepatitis and in Nonalcoholic Fatty Liver Disease

o       357. Homeostasis Model Assessment (HOMA) as a Measurement of Insulin Resistance is Related to Race, Stage, Grade, Body Mass Index but not to Virologic Response to Treatment

o       429. Fibrosis is associated with insulin resistance and steatosis in chronic hepatitis C patients with genotype 1 and 4 but not genotype 3 (updated November 3, 2006)

o       430. Steatosis is associated with intrahepatic HCV RNA level in genotype 3 chronic hepatitis C



o       217. Histologic And Clinical Features Of HCV Cirrhosis: Differences Associated With Race-Ethnicity (updated November 2, 2006)

o       265. Effect of ethnicity on class II HLA associations with HCV clearance and virus-specific CD4 T cell response